Outlook Therapeutics Inc (OTLK)

$0.43 -0.01 (-2.27%)
Market Cap 32.32M
Revenue (ttm) 1.41M
Net Income (ttm) -62.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,426.95%
Debt to Equity Ratio -0.38
Volume 1,016,100
Avg Vol 6,867,966
Day's Range N/A - N/A
Shares Out 73.51M
Stochastic %K 8%
Beta 0.17
Analysts Sell
Price Target $6.10

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therap...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
HolEKa1010
HolEKa1010 Feb. 4 at 2:04 AM
$OTLK getting a little excited to see what the plan is
0 · Reply
Keekster1
Keekster1 Feb. 4 at 12:39 AM
$OTLK added here like the hirings by Danielle
1 · Reply
IniG
IniG Feb. 4 at 12:29 AM
$OTLK Head of Germany & Austria https://www.linkedin.com/in/dr-felix-jede-679273197/
1 · Reply
HarveySpecter20
HarveySpecter20 Feb. 3 at 10:48 PM
$OTLK And another opening for HR just from today, this time for the US and global operations. More than 100 applications within the last 7 hours.
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Feb. 3 at 9:36 PM
$OTLK super bullish..
1 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 9:31 PM
$OTLK Avastin probably has over 100 vendors producing it. LYTENAVA has only one for 10 years
1 · Reply
HarveySpecter20
HarveySpecter20 Feb. 3 at 8:20 PM
$OTLK Hiring goes on, this job add is on for 4 hours now and already got 43 applications. Usually you re increasing HR Capcities if you re planning to increase your headcount.
2 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 7:42 PM
$OTLK LYTENAVA will get buyout
2 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 7:08 PM
$OTLK eylea can sell 200 but EyleaHD will get killed by the price
0 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 6:31 PM
$OTLK 50% market is here and another 50% is 16b
0 · Reply
Latest News on OTLK
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

Jan 6, 2026, 8:35 AM EST - 4 weeks ago

Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

US FDA declines to approve Outlook Therapeutics' eye disease drug

Dec 31, 2025, 4:23 PM EST - 4 weeks ago

US FDA declines to approve Outlook Therapeutics' eye disease drug

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Dec 31, 2025, 4:15 PM EST - 4 weeks ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again

Dec 28, 2025, 8:08 PM EST - 5 weeks ago

Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again

Outlook Therapeutics Announces New Employment Inducement Grants

Dec 26, 2025, 5:00 PM EST - 5 weeks ago

Outlook Therapeutics Announces New Employment Inducement Grants

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Dec 19, 2025, 8:05 AM EST - 6 weeks ago

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 9:05 AM EST - 2 months ago

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Nov 13, 2025, 8:30 AM EST - 2 months ago

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Nov 3, 2025, 8:35 AM EST - 3 months ago

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 29, 2025, 8:45 AM EDT - 4 months ago

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 3, 2025, 8:35 AM EDT - 5 months ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 5 months ago

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 11:51 AM EDT - 5 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 5 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025, 6:39 AM EDT - 5 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Aug 24, 2025, 9:15 AM EDT - 5 months ago

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Aug 14, 2025, 8:05 AM EDT - 6 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 24, 2025, 9:00 AM EDT - 6 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 7 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jul 1, 2025, 8:05 AM EDT - 7 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 18, 2025, 9:05 AM EDT - 8 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 10, 2025, 8:05 AM EDT - 8 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 8 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 23, 2025, 6:30 AM EDT - 9 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 22, 2025, 4:01 PM EDT - 9 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 9 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Apr 8, 2025, 8:45 AM EDT - 10 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 28, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 14, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Feb 4, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 31, 2025, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 23, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 22, 2025, 9:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Jan 16, 2025, 12:09 PM EST - 1 year ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 16, 2025, 6:00 AM EST - 1 year ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 27, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 4, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

Dec 3, 2024, 4:30 PM EST - 1 year ago

Outlook Therapeutics® Announces Executive Leadership Transition

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 9:27 AM EST - 1 year ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 27, 2024, 6:50 AM EST - 1 year ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Nov 6, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 16, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 13, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 4, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

Aug 26, 2024, 4:11 AM EDT - 1 year ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

HolEKa1010
HolEKa1010 Feb. 4 at 2:04 AM
$OTLK getting a little excited to see what the plan is
0 · Reply
Keekster1
Keekster1 Feb. 4 at 12:39 AM
$OTLK added here like the hirings by Danielle
1 · Reply
IniG
IniG Feb. 4 at 12:29 AM
$OTLK Head of Germany & Austria https://www.linkedin.com/in/dr-felix-jede-679273197/
1 · Reply
HarveySpecter20
HarveySpecter20 Feb. 3 at 10:48 PM
$OTLK And another opening for HR just from today, this time for the US and global operations. More than 100 applications within the last 7 hours.
1 · Reply
Knowledgeworthmore
Knowledgeworthmore Feb. 3 at 9:36 PM
$OTLK super bullish..
1 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 9:31 PM
$OTLK Avastin probably has over 100 vendors producing it. LYTENAVA has only one for 10 years
1 · Reply
HarveySpecter20
HarveySpecter20 Feb. 3 at 8:20 PM
$OTLK Hiring goes on, this job add is on for 4 hours now and already got 43 applications. Usually you re increasing HR Capcities if you re planning to increase your headcount.
2 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 7:42 PM
$OTLK LYTENAVA will get buyout
2 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 7:08 PM
$OTLK eylea can sell 200 but EyleaHD will get killed by the price
0 · Reply
AnalystLLM
AnalystLLM Feb. 3 at 6:31 PM
$OTLK 50% market is here and another 50% is 16b
0 · Reply
adayxs
adayxs Feb. 3 at 3:27 PM
$OTLK I have a question for the board. It has been stated that the use of Avastin / Lytenava will drop over the next 5 years. Can someone tell me when a corporation has said, "we will take less profit to benefit others"? The only way the usage will drop is if something cheaper and better comes along. Does anyone have a lead on a cheaper and better treatment?
1 · Reply
mountainman5050
mountainman5050 Feb. 3 at 3:10 PM
$OTLK have a great day longs ✌️🤣💚
0 · Reply
Britbox
Britbox Feb. 3 at 2:58 PM
$OTLK still actively hiring FYI
0 · Reply
Joeydz77
Joeydz77 Feb. 3 at 2:38 PM
$OTLK Good Morning everyone, still waiting to hear some good news from the company, hopefully it'll come soon :)
1 · Reply
Britbox
Britbox Feb. 3 at 1:07 PM
$OTLK Order is in. Hoping to get one last one in on Monday before any news
3 · Reply
SteelerJon
SteelerJon Feb. 3 at 12:28 PM
$OTLK 😎 Still looking….waiting for even a ripple…
0 · Reply
letsride04555
letsride04555 Feb. 3 at 10:07 AM
$OTLK Anyone doing a put option？I mean I’m already down huge. I guess it’s a win win solution😖
1 · Reply
Alder77
Alder77 Feb. 3 at 10:02 AM
$OTLK This company is becoming ridiculous. They should clarify what they want to do. Without the American market, they are unsustainable today, with two miserable markets like England and Germany. No serious company would make any agreement today, not even for a BO, much less a partnership. The underlying assumptions are completely lacking. Unsustainable burn rate, third FDA rejection, almost no cash flow, and non-compliance. Honestly, without clarification from the owners, all I see is drops, dilution, and RS.
1 · Reply
Ehri
Ehri Feb. 3 at 9:43 AM
$OTLK Outlooks third attempt. Will continue
0 · Reply
25_usa
25_usa Feb. 3 at 3:41 AM
$OTLK Partnership with a well-established company (BEST now Why this helps shareholders most at this stage Credibility with FDA Big pharma / established ophthalmology companies know how to deal with FDA CRLs. Non-dilutive cash Upfront payment + milestones = less dilution. Shared regulatory risk Partner may run/finance confirmatory study. Stock rerates immediately Even a modest partnership often doubles distressed biotech stocks. What a good partnership looks like Upfront: $50–100M FDA milestone: $150–300M Tiered royalties: 15–25% Partner leads US FDA strategy Shareholders keep upside and survive to see it. Don’t know which option will bid better but sure it’s happening soon . Partnerships VS Buyout.
1 · Reply
HolEKa1010
HolEKa1010 Feb. 3 at 12:44 AM
$OTLK hang in there! Hopefully some movement one way or the other soon 😎
0 · Reply
Kittyc803
Kittyc803 Feb. 3 at 12:41 AM
$OTLK Still in place 🤦‍♂️ cmon man say something good
0 · Reply